KISQALI 200 mg/1

KISQALI 200 mg is a film-coated tablet used in cancer treatment. It contains ribociclib, a medication often prescribed for specific types of breast cancer. This oral medication is manufactured by Novartis Pharmaceuticals Corporation in the USA.

KISQALI 200 mg is primarily used in the treatment of certain types of breast cancer. It is often prescribed in combination with other medications to help manage the condition. The active ingredient, ribociclib, works by targeting specific proteins involved in cancer cell growth. Patients may wonder, 'What is KISQALI used for?' It is typically used in advanced or metastatic breast cancer cases.

Common effects of KISQALI 200 mg may include fatigue, nausea, and diarrhea. Some patients may experience hair loss or changes in appetite. It is important to discuss any persistent or severe side effects with a healthcare provider. The effects can vary from person to person, and not everyone will experience the same symptoms.

KISQALI 200 mg should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients should inform their doctor about any other medications they are taking to avoid potential interactions. Pregnant women or those planning to become pregnant should consult their healthcare provider before using this medication.

KISQALI 200 mg may interact with certain medications, including those that affect liver enzymes. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Alcohol and other substances may also interact with ribociclib, so it is advisable to discuss any potential interactions with a healthcare professional.